€0.30
Your prediction
India Globalization Capital Stock
Pros and Cons of India Globalization Capital in the next few years
Pros
Cons
Performance of India Globalization Capital vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| India Globalization Capital | -13.220% | -11.696% | -21.354% | 6.338% | 15.267% | -76.769% | -69.013% |
| Celsion Corp. | - | 25.967% | -0.870% | 15.736% | 91.597% | -90.843% | -95.226% |
| Protara Therapeutics Inc. | -3.160% | 0.000% | -14.019% | -11.538% | 8.876% | -67.143% | - |
| CEL-SCI Corp. | -1.740% | -2.899% | -21.546% | -23.282% | -61.047% | -87.978% | -85.791% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of India Global, trading under the symbol IGC in the biotech and medical research sector, provide a fascinating view into a company navigating a challenging landscape. The numbers reflect significant operational challenges and a pressing need for strategic improvements. However, there are also glimpses of potential that could be harnessed with proper management and execution.
At first glance, India Global's financials exhibit a company grappling with substantial obstacles, evidenced by consistent net losses over the past three years—totaling nearly $40 million cumulatively since 2022. Despite a market capitalization of approximately $30.8 million, the high price-to-sales ratio of 26.19 suggests overvaluation relative to revenue. The persistent negative earnings and low revenue figures create uncertainty about the company's profitability and financial viability. However, the presence of cash and inventory indicates that while challenging, the company still has resources to leverage as it seeks growth opportunities.
Substantial Cash Reserves: The most recent balance sheet from March 2024 reveals cash holdings of approximately $1.2 million, providing a safety net to finance operations or pursue strategic investments. Holding cash is vital in the biotechnology sector, where research can be capital-intensive.